ST PHARM

Siheung-si, South Korea Founded: 2008 • Age: 18 yrs
Oligonucleotide, mRNA, and small molecule CDMO services are provided.
Annual revenue $185.6M Latest available
Total funding - 1 rounds
Employees 664 Tracked headcount
Investors 1 Known backers
Products 4 Services tracked
Competitors - Brand Intelligence

About ST PHARM

ST PHARM is a company based in Siheung-si (South Korea) founded in 2008. The company has 664 employees as of December 31, 2024. ST PHARM offers products and services including CDMO Services, CRO Services, Oligonucleotide Services, and mRNA Services.

  • Headquarter Siheung-si, South Korea
  • Employees 664 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name St Pharm Co., Ltd.
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $185.6 M (USD)
    -3.94
    as on Dec 31, 2024
  • Net Profit
    $23.53 M (USD)
    77.27
    as on Dec 31, 2024
  • EBITDA
    $35.95 M (USD)
    -1.91
    as on Dec 31, 2024
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    664

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of ST PHARM

ST PHARM is a publicly listed company on the KRX with ticker symbol 237690 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: KRX · Ticker: 237690 · Sector: Health technology · South Korea

Products & Services of ST PHARM

ST PHARM offers a comprehensive portfolio of products and services, including CDMO Services, CRO Services, Oligonucleotide Services, and mRNA Services.

Product name locked
Category locked
Primary

Contract development and manufacturing for pharmaceuticals and gene therapy.

Product name locked
Category locked
Locked

Contract research and development for biotechnology and R&D projects.

Product name locked
Category locked
Locked

Manufacturing and development of oligonucleotide-based therapies.

Product name locked
Category locked
Locked

Contract production and research for mRNA technologies.

Funding Insights of ST PHARM

Investors in ST PHARM

ST PHARM has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include E&Investment.

All
Venture Fund
Investor Description Founded Year Domain Location
-
Locked Locked Locked
Premium access

Investor details for ST PHARM

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by ST PHARM

Investments
Premium access

Investment portfolio details for ST PHARM

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - ST PHARM

Premium access

Detailed financials for ST PHARM

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

St Pharm Comparisons

ST PHARM Primary company
Description
Oligonucleotide, mRNA, and small molecule CDMO services are ...
Location
Siheung-si, South Korea
Founded Year
2008
Annual Revenue
$185.6 M (USD)
Net Profit
$23.53 M (USD)
EBITDA
$35.95 M (USD)
Employees
664
As of 2024
Premium access

Peer comparison for ST PHARM

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of ST PHARM

Premium access

Detailed competitors of ST PHARM

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on St Pharm

Premium access

Complete news archive for ST PHARM

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about ST PHARM

ST PHARM was founded in 2008 and raised its 1st funding round 7 years after it was founded.

ST PHARM is headquartered in Siheung-si, South Korea. It is registered at Siheung-si, Gyeonggi-do, South Korea.

As of Dec 31, 2024, the latest employee count at ST PHARM is 664.

Annual revenue of ST PHARM is $185.6M as on Dec 31, 2024.

Founded in 2008, ST PHARM functions as a contract development and manufacturing organization in the pharmaceutical sector. Services are extended across oligonucleotide, mRNA, and small molecule modalities, including research and development with virtual and global capabilities. Analytical testing and quality control are conducted to support clients from early-stage drug research to commercial production stages. Operations are based in South Korea.

ST PHARM offers CDMO Services, CRO Services, Oligonucleotide Services, and mRNA Services.

Yes, ST PHARM is publicly traded on KRX under the ticker symbol 237690.

ST PHARM has 1 investor. Key investors include E&Investment.

The ticker symbol of ST PHARM is 237690 on KRX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available